Report dashes hopes for new use for blockbuster weight-loss drug<ul><li><a href="https://www.theguardian.com/business/live/2025/nov/24/bhp-walks-away-takeover-approach-anglo-mining-merger-uk-budget-cbi-ftse-pound-business-live-news">Business live – latest updates</a></li></ul>Novo Nordisk shares slumped on Monday after the drugmaker said the pill version of its weight-loss drug Ozempic had failed to slow the progression of Alzheimer’s disease in two large studies.The Danish company said patients who took the drug did not see their disease progress more slowly, dashing hopes for a new use for the blockbuster diabetes drug. <a href="https://www.theguardian.com/business/2025/nov/24/novo-nordisk-shares-ozempic-alzheimers-trials-weight-loss-drug">Continue reading...</a>

انخفضت أسهم شركة نوفو نورديسك بشكل كبير بعد أن أعلنت الشركة أن النسخة الحبوب من دواء فقدان الوزن أوزمبك لم تتمكن من إبطاء تقدم مرض الزهايمر في دراستين كبيرتين. هذه النتيجة أجهضت الآمال في استخدام جديد للدواء، الذي كان ناجحًا في علاج السكري.

Las acciones de Novo Nordisk cayeron drásticamente después de que la compañía anunciara que la versión en píldora de su medicamento para la pérdida de peso, Ozempic, no logró frenar la progresión de la enfermedad de Alzheimer en dos grandes estudios. Este resultado desvaneció las esperanzas de un nuevo uso para el medicamento, que ha sido un éxito en el tratamiento de la diabetes.

Les actions de Novo Nordisk ont chuté de manière significative après que la société a annoncé que la version pilule de son médicament contre la perte de poids, Ozempic, n'avait pas ralenti la progression de la maladie d'Alzheimer dans deux grandes études. Ce résultat a anéanti les espoirs d'une nouvelle utilisation du médicament, qui a été un succès commercial dans le traitement du diabète.

Novo Nordisk shares fell significantly after the company announced that the pill version of its weight-loss drug Ozempic did not slow the progression of Alzheimer’s disease in two major studies. This outcome dashed hopes for a new application of the drug, which has been a blockbuster in diabetes treatment.

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Rolling coverage of the latest economic and financial news, as Novo Nordisk finds its semaglutide drug fails to help in Alzheimer’s treatmentGerman business morale has unexpectedly fallen this month, as companies lose hope on a recovery of the German economy following two years of contraction.The Ifo institute has reported that its business climate index fell to 88.1 in November from 88.4 in October, weaker than expected. It’s a blow to German chancellor Friedrich Merz’s efforts to revive growth through a major spending package.“Companies have little faith that a recovery is coming anytime soon.”Like U2 sang almost 40 years ago: the German economy still hasn’t found what it’s looking for.The year 2025 has been another year of hope and disappointed optimism. A year which saw excitement and enthusiasm sparked by Germany’s unprecedented fiscal policy U-turn and its decision to invest significantly in infrastructure and defence this spring. But also a year that brought a rude awakening and a cringing feeling as we watched the new government undermine the positive impact of fiscal stimulus with clumsy budgetary decisions, new political tensions, and a lack of structural reforms. <a href="https://www.theguardian.com/business/live/2025/nov/24/bhp-walks-away-takeover-approach-anglo-mining-merger-uk-budget-cbi-ftse-pound-business-live-news">Continue reading...</a>

انخفضت أسهم شركة نوفو نورديسك بشكل كبير بعد الإعلان عن أن حبوب أوزيمبيك لم تؤخر تقدم مرض الزهايمر في دراستين رئيسيتين. تأتي هذه الأخبار في ظل مخاوف اقتصادية أوسع، بما في ذلك انخفاض معنويات الأعمال في ألمانيا بينما تكافح البلاد للتعافي من عامين من الانكماش الاقتصادي.

Las acciones de Novo Nordisk han caído significativamente tras el anuncio de que su píldora Ozempic no ralentizó la progresión de la enfermedad de Alzheimer en dos estudios importantes. Esta noticia llega en medio de preocupaciones económicas más amplias, incluida una caída en la moral empresarial alemana mientras el país lucha por recuperarse de dos años de contracción económica.

Les actions de Novo Nordisk ont considérablement chuté après l'annonce que sa pilule Ozempic n'a pas ralenti la progression de la maladie d'Alzheimer dans deux grandes études. Cette nouvelle survient dans un contexte économique plus large, notamment une baisse du moral des entreprises allemandes alors que le pays peine à se remettre de deux années de contraction économique.

Shares of Novo Nordisk have significantly declined following the announcement that its Ozempic pill did not slow the progression of Alzheimer’s disease in two major studies. This news comes amid broader economic concerns, including a drop in German business morale as the country struggles to recover from two years of economic contraction.

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Was this article worth reading? Share it